Rigel Pharmaceuticals, Inc. (RIGL) has kicked off 2025 with strong financial results, delivering a profitable first quarter on the back of rising product sales and strategic pipeline investments.
Rigel is a commercial-stage biotech company focused on hematologic disorders and cancer. Its marketed therapies include TAVALISSE, GAVRETO, and REZLIDHIA, targeting conditions such as immune thrombocytopenia, RET-altered cancers, and relapsed/refractory AML, respectively.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com